Drug repurposing and the prior art patents of competitors

Drug Discovery Today

Volumn 19, Issue 12, 2014, Pages 1841-1847

  Sternitzke, Christian ^a,b  

^a CFH Beteiligungsgesellschaft MbH   (Germany)

^b ILMENAU UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

AUTOIMMUNE DISEASE; BLADDER DISEASE; DEPRESSION; DRUG INDICATION; DRUG REPOSITIONING; EPILEPSY; ERECTILE DYSFUNCTION; FEMALE SEXUAL DYSFUNCTION; FIBROSIS; HUMAN; INFORMATION RETRIEVAL; NEOPLASM; NEUROPATHY; PATENT; PROSTATE HYPERTROPHY; PUBLICATION; PUBLISHING; PULMONARY HYPERTENSION; REVIEW; UNITED STATES; ANIMAL; AUTOIMMUNE DISEASES; DRUG INDUSTRY; HYPERTENSION, PULMONARY; MALE; NERVOUS SYSTEM DISEASES; PROSTATIC HYPERPLASIA; URINARY BLADDER DISEASES;

ANIMALS; AUTOIMMUNE DISEASES; DRUG INDUSTRY; DRUG REPOSITIONING; ERECTILE DYSFUNCTION; HUMANS; HYPERTENSION, PULMONARY; MALE; NERVOUS SYSTEM DISEASES; PATENTS AS TOPIC; PHOSPHODIESTERASE 5 INHIBITORS; PROSTATIC HYPERPLASIA; URINARY BLADDER DISEASES;

EID: 84919363345     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.09.016     Document Type: Short Survey

References (17)

1. T.T. Ashburn, and K.B. Thor Drug repositioning: identifying and developing new uses for existing drugs Nat. Rev. Drug Discov. 3 2004 673 683
2. J. Arrowsmith, and R. Harrison Drug repositioning: the business case and current strategies to repurpose shelved candidates and marketed drugs M.J. Barratt, D.E. Frail, Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs 2012 Wiley 9 32
3. J.A. DiMasi The price of innovation: new estimates of drug development costs J. Health Econ. 22 2003 151 185
4. P. Sandner, and K. Ziegelbauer Product-related research: how research can contribute to successful life-cycle management Drug Discov. Today 13 2008 457 463
5. S.H. Sleigh, and C.L. Barton Repurposing strategies for therapeutics Pharm. Med. 24 2010 151 159
6. R.B. Smith Repositioned drugs: integrating intellectual property and regulatory strategies Drug Discov. Today Ther. Strat. 8 2012 131 137
7. M.J. Barratt, and D.E. Frail Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs 2012 Wiley
8. E.L. Tobinick The value of drug repositioning in the current pharmaceutical market Drug News Perspect. 22 2009 119 125
9. E. Mansfield Patents and innovation: an empirical study Manage. Sci. 32 1986 173 181
10. T. Amin, and A.S. Kesselheim Secondary patenting of branded pharmaceuticals: a case study of how patents on two HIV drugs could be extended for decades Health Affairs 31 2012 2286 2294
11. L. Howard Use of patents in drug lifecycle management J. Generic Med. 4 2007 230 236
12. C. Sternitzke An exploratory analysis of patent fencing in pharmaceuticals: the case of PDE5 inhibitors Res. Policy 42 2013 542 551
13. T. Peters Protecting growth options in dynamic markets: the role of strategic disclosure in integrated intellectual property strategies Calif. Manage. Rev. 55 2013 121 142
14. B. Barrett Defensive use of publications in an intellectual property strategy Nat. Biotech. 20 2002 191 193
15. D.E. Frail, and M.J. Barratt Opportunities and challenges associated with developing additional indications for clinical development candidates and marketed drugs M.J. Barratt, D.E. Frail, Drug Repositioning: Bringing New Life to Shelved Assets and Existing Drugs 2012 Wiley 33 51
16. T.X. Witkowski Intellectual property and other legal aspects of drug repurposing Drug Discov. Today: Ther. Strat. 8 2012 139 143
17. S. Wagner, and S.D. Wakeman What do Patent-based Measures tell Us about Product Commercialization? Evidence from the Pharmaceutical Industry 2014 ESMT Working Paper